Display options
Cite
Das A, Wei G, Parikh K, et al. Selective inhibitors of nuclear export (SINE) in hematological malignancies. Exp Hematol Oncol. 2015;4:7doi: 10.1186/s40164-015-0002-5.
Das, A., Wei, G., Parikh, K., & Liu, D. (2015). Selective inhibitors of nuclear export (SINE) in hematological malignancies. Experimental hematology & oncology, 47. https://doi.org/10.1186/s40164-015-0002-5
Das, Arundhati, et al. "Selective inhibitors of nuclear export (SINE) in hematological malignancies." Experimental hematology & oncology vol. 4 (2015): 7. doi: https://doi.org/10.1186/s40164-015-0002-5
Das A, Wei G, Parikh K, Liu D. Selective inhibitors of nuclear export (SINE) in hematological malignancies. Exp Hematol Oncol. 2015 Mar 01;4:7. doi: 10.1186/s40164-015-0002-5. eCollection 2015. PMID: 25745591; PMCID: PMC4350974.
Copy Download .nbib Format: NLM
Share it on

Exp Hematol Oncol. 2015 Mar 01;4:7. doi: 10.1186/s40164-015-0002-5. eCollection 2015.

Selective inhibitors of nuclear export (SINE) in hematological malignancies.

Experimental hematology & oncology

Arundhati Das, Guoqing Wei, Kaushal Parikh, Delong Liu

Affiliations

  1. Department of Medicine, Westchester Medical Center, Valhalla, NY 10595 USA.
  2. Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  3. Henan Cancer Hospital, Zhengzhou University, Zhengzhou, China.

PMID: 25745591 PMCID: PMC4350974 DOI: 10.1186/s40164-015-0002-5

Abstract

Regulated nucleo-cytoplasmic transport plays a major role in maintaining cellular homeostasis. CRM1 (chromosome region maintenance 1 or exportin 1 or XPO 1) is responsible for the nucleo-cytoplasmic transport of more than 200 proteins, including most of the tumor suppressor proteins (TSP). CRM1 is overexpressed in pancreatic cancer, osteosarcoma, glioma, cervical and hematological malignancies. This inspired the development of novel agents that selectively inhibit nuclear exportins (SINEs). In this review we focus on the significance of CRM1 in carcinogenesis and review the new development of SINE inhibitiors in hematological malignancies. Selinexor (KPT-330) as the first-in-human SINE agent represents this novel class of anti-cancer agents.

Keywords: KPT-330; SINE; Selective inhibitor of nuclear export; Slinexor

References

  1. Blood. 2012 Nov 29;120(23):4621-34 - PubMed
  2. PLoS One. 2014 Feb 04;9(2):e87585 - PubMed
  3. Mol Cell. 2004 Dec 3;16(5):761-75 - PubMed
  4. Am J Clin Pathol. 2010 Jan;133(1):34-40 - PubMed
  5. Blood. 2012 Aug 30;120(9):1765-73 - PubMed
  6. J Hematol Oncol. 2013 Mar 27;6:23 - PubMed
  7. Leukemia. 2014 Jan;28(1):155-65 - PubMed
  8. Mol Biol Cell. 2012 Sep;23(18):3673-6 - PubMed
  9. Leukemia. 2013 Dec;27(12):2357-65 - PubMed
  10. Biophys J. 2010 Apr 21;98(8):1658-67 - PubMed
  11. Br J Haematol. 2013 Apr;161(1):117-27 - PubMed
  12. Cancer Sci. 2014 Jul;105(7):795-801 - PubMed
  13. J Hematol Oncol. 2014 Oct 04;7:74 - PubMed
  14. Nature. 2009 Apr 30;458(7242):1136-41 - PubMed
  15. Blood. 2013 May 16;121(20):4166-74 - PubMed
  16. Blood. 2013 Oct 24;122(17):3034-44 - PubMed
  17. J Hematol Oncol. 2011 Sep 14;4:36 - PubMed
  18. J Hematol Oncol. 2014 Oct 15;7:78 - PubMed
  19. Blood. 2013 Oct 24;122(17):2926-8 - PubMed
  20. J Hematol Oncol. 2014 Dec 05;7:85 - PubMed
  21. J Cell Biol. 1989 Apr;108(4):1195-207 - PubMed
  22. J Hematol Oncol. 2014 Oct 05;7:46 - PubMed
  23. J Hematol Oncol. 2014 Sep 10;7:55 - PubMed
  24. J Hematol Oncol. 2014 Oct 04;7:67 - PubMed
  25. Haematologica. 2013 Jul;98(7):1098-106 - PubMed
  26. J Biol Chem. 2012 Mar 30;287(14):11030-6 - PubMed
  27. Hematology Am Soc Hematol Educ Program. 2010;2010:47-55 - PubMed
  28. Br J Cancer. 1996 Aug;74(4):648-9 - PubMed
  29. Exp Hematol. 2013 Jan;41(1):67-78.e4 - PubMed
  30. Curr Med Chem. 2008;15(26):2648-55 - PubMed
  31. Cell. 1997 Sep 19;90(6):1051-60 - PubMed
  32. Semin Cancer Biol. 2014 Aug;27:52-61 - PubMed

Publication Types